Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
about
Trastuzumab-containing regimens for metastatic breast cancerFirst-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast CancerABC3 Consensus Commented from the Perspective of the German GuidelinesNational consensus in China on diagnosis and treatment of patients with advanced breast cancerHuman epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsTargeted therapy for HER2 positive breast cancerNeoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implicationsRole of trastuzumab emtansine in the treatment of HER2-positive breast cancerSerum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsIntermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk.Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerBeyond RAS and BRAF: a target rich disease that is ripe for pickingRecent developments and translational aspects in targeted therapy for metastatic breast cancerResistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesCardiac risk in the treatment of breast cancer: assessment and management.Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugatesTheranostic nanoparticlesABC3 Consensus: Assessment by a German Group of ExpertsAdjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell TransplantationBiomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.Trastuzumab emtansine: mechanisms of action and drug resistanceAn open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.Clinical impact of tumour biology in the management of gastroesophageal cancerTherapeutic options for HER-2 positive breast cancer: Perspectives and future directionsImproved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabelingEffect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review.Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine.Therapeutic Considerations in Treating HER2-Positive Metastatic Breast CancerCurrent status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistanceLapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.The molecular genomics of metastatic brain tumours.Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy.Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study.Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.
P2860
Q24194019-1436EFFF-DD51-48E7-9C0F-A9F95CC6FAD2Q26746081-A0623B32-DE36-45E6-AB3A-AF7D48DA6A47Q26764987-7C261437-CC0B-4A45-9708-337AAE994123Q26768665-72B30526-287E-4853-B65F-D0C7001C349CQ26775621-782C4795-CC90-4D9C-933A-E0CDCCED7A7FQ26777681-9037EFA9-D869-4641-92FE-77E50FD101DEQ26830496-A94D379F-D22D-4FC9-B815-84F3DFA574A6Q27001729-18D29F84-CC4E-40F9-ABFF-AFF116CA0989Q27003258-718AEBA9-7BE9-4C42-B6BA-9A68F3968827Q27007849-8D94C216-E6F1-478C-8789-28DB09C21A59Q27315979-8B339A39-478B-4796-BA2F-17A4109B450CQ27853134-BAC4FF73-5A78-4CB5-8ED0-3C3B4E344F83Q28066095-93FFD596-6FFB-498D-897C-284BD9B3EA80Q28072755-E86222EC-4D5A-4D79-9C5A-F148FB8EDE42Q28072897-36F2D38A-1A48-4A8F-A524-C2B19762CCB2Q28081385-E35E2E0C-C9CA-48EE-B0AC-F5AA551B1CFEQ28083123-2A2C199B-9AB9-44C3-9BBF-57251A4DE531Q28650348-D95BE507-3A5B-4793-A4B7-E12E289058A7Q30315301-63FAC8AB-9E8C-46B0-9D0E-98B2308BEBE1Q30758991-B1871C34-D6DA-40B1-83D7-467E0A5D4076Q30857631-33DD4515-8BF3-4587-8AEC-9C20DFBA4D34Q33411110-C0DB4A5B-13C8-44D9-AE50-5261050510B2Q33571352-FF090F45-5722-47F4-BA62-A8B71C810E5BQ33573092-E51A5B5B-6EF9-4F91-B6EB-011BD487C156Q33759627-DE27971F-7A31-4301-AE5F-270328EA3421Q33777427-FEE04546-873F-44A9-806D-195E343BB241Q33827808-95E9344D-8A29-4CDC-BAB5-4625AD6F29EFQ33877385-6623E37D-93B9-40DE-A52F-AA8FA96CBC56Q33922534-A9A058D6-D94C-4EFE-B331-9B787E82F57FQ34023704-73920ADB-228D-4E8F-A87F-B667A12577ECQ34148890-4FB5E0B5-307E-4E8E-9516-96F770C55B72Q34169075-ED061394-DDF3-4EC9-9D76-EDE21BC35AF6Q34181224-361AEB57-E519-4F4C-B1AD-3573525C16EBQ34268618-7B6463A7-BBB5-4F04-9307-B574F379B7DBQ34355748-C57C2CF9-5B94-4B25-90E2-109DCBD28BD4Q34372166-9B0BB150-D6FE-4B4D-85E4-487EF26BB248Q34499855-E0A377A1-82A3-48E8-A6E1-A699E394F956Q34567451-E3CAECC5-A51B-439E-90A6-D71878A5FAF3Q34641036-7CBA17F1-886C-4B9D-8761-3D1CC5DE8C14Q34664129-404454D7-1682-470D-A6B8-B312A0E878F2
P2860
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Overall survival benefit with ...... ults from the EGF104900 Study.
@en
Overall survival benefit with ...... ults from the EGF104900 Study.
@nl
type
label
Overall survival benefit with ...... ults from the EGF104900 Study.
@en
Overall survival benefit with ...... ults from the EGF104900 Study.
@nl
prefLabel
Overall survival benefit with ...... ults from the EGF104900 Study.
@en
Overall survival benefit with ...... ults from the EGF104900 Study.
@nl
P2093
P356
P1476
Overall survival benefit with ...... ults from the EGF104900 Study.
@en
P2093
Allison Florance
Anna Maria Storniolo
Catherine Ellis
George Sledge
Gursel Aktan
Harold J Burstein
Hope S Rugo
Joachim Bischoff
José Baselga
Joyce O'Shaughnessy
P304
P356
10.1200/JCO.2011.35.6725
P407
P577
2012-06-11T00:00:00Z